[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574990":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":25,"locations":31,"responsibleParty":48,"collaborators":52,"id":57,"slug":12,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":12,"enrollmentInfo":65,"targetDuration":12,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":34,"whyStopped":12,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control","NO_INTERVENTION","This arm will receive standard of care according to local protocol.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Intervention","EXPERIMENTAL","This arm will be treated with double dosages of beta-lactam antibiotics the first 48 hours after inclusion.",[18],"Drug: Double dosing of beta-lactam antibiotic",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DRUG","Double dosing of beta-lactam antibiotic","This arm will receive double dosing of beta-lactam antibiotics for the first 48 hours after inclusion.",[14],[26],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},"Birgit C.P. Koch, PharmD","CONTACT","0031107033202","b.koch@erasmusmc.nl",[32],{"facility":33,"status":34,"city":35,"state":12,"zip":12,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Maasstad Ziekenhuis","RECRUITING","Rotterdam","Netherlands",{"type":38,"coordinates":39},"Point",[40,41],4.47917,51.9225,{"lat":41,"lon":40},[44],{"name":45,"role":28,"phone":46,"phoneExt":12,"email":47},"Dr. Den Uil","0031102913474","uilc@maasstadziekenhuis.nl",{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Birgit Koch","Principal Investigator",[53,55],{"name":54,"class":6},"Maasstad Hospital",{"name":56,"class":6},"Albert Schweitzer Hospital","100574990",false,"NCT06766461","Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis","BULLSEYE","Inclusion Criteria:\n\n* ≥18 years of age\n* Receiving intravenous antibiotic therapy of the target drugs (including continuous infusion of beta-lactam antibiotics)\n* Primary infection\n* Admitted to the ICU\n* Meeting the Sepsis-3 criteria for septic shock: sepsis in addition to shock requiring the start of vasopressors to maintain a mean arterial pressure 65 mmHg or greater, and a serum lac tate level greater than 2.0 mmol\u002FL following \"adequate fluid resuscitation\".\n\nExclusion Criteria:\n\n* Patient or legal representative not available to give informed consent within 72 hours after admittance\n* Pregnancy\n* Admittance for burn wounds\n* Patients receiving target antibiotics only as prophylaxis within the context of Selective Diges tive tract Decontamination (SDD)\n* Enrolment in another interventional trial\n* Patient received the study antibiotic for more than 24 hours before inclusion\n* Patient receiving extracorporeal membrane oxygenation (ECMO)\n* Patient is already treated with a double dose of antibiotics based on suspected infection","ALL","18 Years",{"count":66,"type":67},980,"ESTIMATED","INTERVENTIONAL",[70],"PHASE4","The aim of this study is to investigate if an initial short double dose of beta-lactam antibiotics will reduce mortality in critically ill patients with sepsis.",[73,74,75],"Sepsis - to Reduce Mortality in the Intensive Care Unit","Sepsis","Septic Shock",[77,78,79,80,81],"sepsis","intensive care","critically ill","antibiotic","septic shock","2025-01-08",{"date":84,"type":85},"2025-01-09","ACTUAL",{"date":87,"type":85},"2025-01-03",{"date":89,"type":67},"2027-12-01",{"name":5,"class":6},1]